ICON Shareholders Vote In Favour Of All Resolutions At Its Annual General Meeting

ICON plc , (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on 22 nd July 2013 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders on 14 th June 2013 and are available on the ICON plc website.

The final results of voting on each of the items submitted to a vote of shareholders during the AGM are as follows:

RESOLUTIONNUMBER
  RESOLUTION   TOTAL NUMBER OF VOTES   VOTE FOR   VOTE AGAINST   VOTE WITHHELD    
 
1.1 To re-elect Mr. Thomas Lynch 51,674,203 51,474,431 133,020 66,752
 
1.2 To re-elect Mr. Declan McKeon 51,674,203 51,506,997 100,445 66,761
 
1.3 To re-elect Prof. William Hall 51,674,203 51,517,884 89,558 66,761
 
2 To receive accounts and reports 51,674,203 51,409,116 8,517 256,570
 
3 To authorise the fixing of the auditors’ remuneration 51,674,203 47,640,947 3,965,491 67,765
 
4 To authorise the Company to allot shares 51,674,203 44,580,855 7,013,214 80,134
 
5** To disapply pre-emption rights 51,674,203 45,337,820 6,251,874 84,509
 
6** To authorise the Company to make market purchases of shares 51,674,203 51,122,122 13,329 538,752
 

** Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 78 locations in 37 countries and has approximately 10,170 employees. Further information is available at www.iconplc.com.

ICON/ICLR-F

Copyright Business Wire 2010